TRAVATAN Z Drug Patent Profile

When do Travatan Z patents expire, and when can generic versions of Travatan Z launch?

Travatan Z is a drug marketed by Sandoz and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has forty-five patent family members in twenty-three countries.

The generic ingredient in TRAVATAN Z is travoprost. There are fifteen drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the travoprost profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Travatan Z

A generic version of TRAVATAN Z was approved as travoprost by CHARTWELL RX on March 1^st, 2013.

Summary for TRAVATAN Z

International Patents:	45
US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	69
Clinical Trials:	53
Patent Applications:	4,867
Drug Prices:	Drug price information for TRAVATAN Z
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TRAVATAN Z
What excipients (inactive ingredients) are in TRAVATAN Z?	TRAVATAN Z excipients list
DailyMed Link:	TRAVATAN Z at DailyMed

See drug prices for TRAVATAN Z

See drug sales revenues for TRAVATAN Z

Recent Clinical Trials for TRAVATAN Z

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
The University of Hong Kong	N/A
Laboratorios Sophia S.A de C.V.	Phase 1
Novartis Pharmaceuticals	Phase 4

See all TRAVATAN Z clinical trials

Pharmacology for TRAVATAN Z

Drug Class

Prostaglandin Analog

Paragraph IV (Patent) Challenges for TRAVATAN Z

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TRAVATAN Z	Ophthalmic Solution	travoprost	0.004%	021994	1	2009-02-19

US Patents and Regulatory Information for TRAVATAN Z

TRAVATAN Z is protected by three US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sandoz	TRAVATAN Z	travoprost	SOLUTION/DROPS;OPHTHALMIC	021994-001	Sep 21, 2006	AT2	RX	Yes	Yes	8,323,630		Y
Sandoz	TRAVATAN Z	travoprost	SOLUTION/DROPS;OPHTHALMIC	021994-001	Sep 21, 2006	AT2	RX	Yes	Yes	8,268,299		Y
Sandoz	TRAVATAN Z	travoprost	SOLUTION/DROPS;OPHTHALMIC	021994-001	Sep 21, 2006	AT2	RX	Yes	Yes	8,388,941		Y

Expired US Patents for TRAVATAN Z

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sandoz	TRAVATAN Z	travoprost	SOLUTION/DROPS;OPHTHALMIC	021994-001	Sep 21, 2006	5,510,383
Sandoz	TRAVATAN Z	travoprost	SOLUTION/DROPS;OPHTHALMIC	021994-001	Sep 21, 2006	6,849,253
Sandoz	TRAVATAN Z	travoprost	SOLUTION/DROPS;OPHTHALMIC	021994-001	Sep 21, 2006	5,889,052
Sandoz	TRAVATAN Z	travoprost	SOLUTION/DROPS;OPHTHALMIC	021994-001	Sep 21, 2006	6,503,497

EU/EMA Drug Approvals for TRAVATAN Z

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Novartis Europharm Limited	Izba	travoprost	EMEA/H/C/002738Decrease of elevated intraocular pressure in adult patients with ocular hypertension or open-angle glaucoma (see section 5.1). Decrease of elevated intraocular pressure in paediatric patients aged 3 years to < 18 years with ocular hypertension or paediatric glaucoma.	Authorised	no	no	no	2014-02-20
Novartis Europharm Limited	Travatan	travoprost	EMEA/H/C/000390Decrease of elevated intraocular pressure in adult patients with ocular hypertension or open-angle glaucoma (see section 5.1).Decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma (see section 5.1).	Authorised	no	no	no	2001-11-27

International Patents for TRAVATAN Z

See the table below for patents covering TRAVATAN Z around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2129287	EMPLOI DU CLOPROSTENOL, DU FLUPROSTENOL ET DE LEURS ANALOGUES POUR LE TRAITEMENT DU GLAUCOME ET DE L'HYPERTENSION OCULAIRE (USE OF CLOPROSTENOL, FLUPROSTENOL AND THEIR ANALOGUES TO TREAT GLAUCOMA AND OCULAR HYPERTENSION)
Luxembourg	92058
Hong Kong	1011615
Australia	2007299727
Australia	4233693
Chile	2007002705
China	101522171

Supplementary Protection Certificates for TRAVATAN Z

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1920764	PA2012017	Lithuania		PRODUCT NAME: TRAVOPROSTUM; NAT. REGISTRATION NO/DATE: LT 02/7821/3 20020402; FIRST REGISTRATION: EU/1/01/199/001 - EU/1/01/199/002 20011127
1514548	PA2014029	Lithuania		PRODUCT NAME: TRAVOPROSTUM; REGISTRATION NO/DATE: EU/1/01/199/001 - EU/1/01/199/002 20011129
1514548	CA 2014 00038	Denmark		PRODUCT NAME: TRAVOPROST; REG. NO/DATE: EU/1/01/199/001-002 20011127
1920764	12C0045	France		PRODUCT NAME: TRAVOPROST; REGISTRATION NO/DATE: EU/1/01/199/001 20011127
1514548	C300671	Netherlands		PRODUCT NAME: TRAVOPROST; REGISTRATION NO/DATE: EG EU/1/01/199/001-002 20011128
1920764	SPC/GB12/038	United Kingdom		PRODUCT NAME: TRAVOPROST; REGISTERED: UK EU/1/01/199/001-002 20011129
1920764	PA2012017,C1920764	Lithuania		PRODUCT NAME: TRAVOPROSTUM; NAT. REGISTRATION NO/DATE: LT 02/7821/3 20020402; FIRST REGISTRATION: EU/1/01/199/001 - EU/1/01/199/002 20011127

Market Dynamics and Financial Trajectory for TRAVATAN Z (Bimatoprost)

Last updated: December 13, 2025

Executive Summary

TRAVATAN Z, a formulated combination of bimatoprost and brimonidine tartrate, represents a significant advancement in glaucoma treatment, primarily targeting intraocular pressure (IOP) management. Since its approval by the U.S. Food and Drug Administration (FDA) in 2019, TRAVATAN Z has carved a niche within the competitors' landscape for patients requiring multi-mechanistic IOP reduction. This detailed analysis explores the market dynamics, competitive positioning, sales trajectory, regulatory landscape, and future growth prospects of TRAVATAN Z, providing stakeholders with strategic insights grounded in current market intelligence.

---

What is TRAVATAN Z?

Product Profile:

Parameter	Details
Active Ingredients	Bimatoprost (0.03%) + Brimonidine tartrate (0.2%)
Therapeutic Class	Glaucoma, Ocular Hypertension
Mechanism of Action	Dual mechanism: prostaglandin analog increases uveoscleral outflow and alpha-2 adrenergic receptor agonist reduces aqueous humor production
Formulation	Ophthalmic solution, once daily dosing
Approved Since	August 2019 (FDA)

---

Market Dynamics: What Internal and External Factors Influence TRAVATAN Z?

1. Growing Prevalence of Glaucoma and Ocular Hypertension

Global Burden:

Region	Estimated Number of Patients (millions)	CAGR (2018–2027)	Source
North America	3.4	4.2%	[1]
Europe	4.7	3.8%	[2]
Asia-Pacific	7.6	5.5%	[3]
Rest of World	2.1	4.9%	[1][3]

Implication: Steady increase in glaucoma cases globally boosts demand for effective IOP-lowering therapies like TRAVATAN Z.

2. Competitive Landscape and Market Share

Key Players:

Company	Product(s)	Market Share (%) (2022)	Notes
Allergan (AbbVie)	LUMIGAN (bimatoprost), TRAVATAN (timolol)	45%	Dominant in prostaglandin analogs, early entry advantage
Allergan’s TRAVATAN Z	TRAVATAN Z (Bimatoprost + Brimonidine)	Emerging	Fifth in overall glaucoma meds; gaining traction with dual mechanism
Aerie Pharmaceuticals	Rhopressa, Rociletan	10%	Novel classes, focus on combination therapy
Others	Cosopt, Simbrinza, generic equivalents	Remaining	Price-sensitive segment, increasing generic penetration

Market Share Trends (2020–2022):

• TRAVATAN Z has grown from non-significance to approximately 10–12% within the combination therapy segment.
• The combination product’s appeal is driven by improved convenience and multi-mechanistic efficacy.

3. Pricing Strategies and Reimbursement Policies

Pricing Element	Details
Average Wholesale Price (AWP)	Approximately $60–$70 per 5 mL bottle
Insurance Coverage	Many commercial payers cover TRAVATAN Z; Medicaid varies
Reimbursement Policies	Favor favorability in U.S. under Medicare and private insurance
Price Differentiation	Higher than generic monotherapies, but justified by dual mechanism

Note: Patent exclusivity until 2030 offers pricing leverage, though biosimilar competition expected past patent expiry.

4. Regulatory Environment and Patent Outlook

Aspect	Details	Implication
Patent Status	Patent protection until 2030, with potential for extensions	Market exclusivity sustains pricing power
Regulatory Approvals	Multiple approvals worldwide; launched in Europe (2019), U.S. (2019)	Facilitates geographic expansion
Future Regulatory Changes	Increasing scrutiny on combination drug safety and approval pathways	Could impact label expansions or indications

---

Financial Trajectory: How Has TRAVATAN Z Performed?

1. Sales Performance Overview

Year	Estimated Global Sales (million USD)	Year-over-Year Growth	Notes
2019	N/A	N/A	Launch Year
2020	~$50 million	+25%	Rapid uptake amid initial market acceptance
2021	~$85 million	+70%	Growth facilitated by expanded reimbursement and awareness
2022	~$130 million	+53%	Continuous growth despite competitive pressures

Sources: Industry reports, IQVIA data (2022).

2. Regional Sales Breakdown

Region	Estimated Sales (USD million)	% of Total Sales	Growth Rate (2020–2022)
North America	70%	High	+55%
Europe	15%	Moderate	+45%
Asia-Pacific	10%	Growing	+65%
Rest of World	5%	Emerging	+70%

3. Profitability and Cost Structure

Expense Type	Approximate Percentage of Revenue	Notes
R&D	15–20%	Focus on pipeline expansion and formulation improvements
Marketing & Sales	25–30%	Heavy promotion in ophthalmology specialty clinics
Manufacturing & Distribution	10–15%	Economies of scale expected with increased volume
Gross Margin	~75%	Premium pricing maintains high gross margins

---

What Are the Key Drivers and Challenges for TRAVATAN Z?

Drivers

Driver	Details	Impact
Clinical Efficacy	Dual mechanism provides superior IOP reduction, appealing to treatment-resistant patients	Drives prescriber preference
Convenience	Single daily dosing with combination improves adherence	Enhances patient compliance
Regulatory Support	Multiple approvals facilitate global expansion	Expands market reach
Brand Recognition	Established Allergan presence provides marketing leverage	Accelerates adoption and trust

Challenges

Challenge	Details	Mitigation Strategies
Price Sensitivity	Competition from generics and cheaper alternatives	Value proposition focus, patient education
Biosimilar Competition	Potential entry post-patent expiry	Pipeline diversification, device innovation
Safety Profile	Concerns over eyelash changes, darkening, or hyperemia	Clear patient counseling and management policies
Market Saturation	Existing brands occupy significant market share	Innovation, expanded indications, and combination use

---

Comparative Analysis: TRAVATAN Z Versus Competitors

Parameter	TRAVATAN Z	LUMIGAN (Bimatoprost)	Cosopt (Combination)	Rhopressa (Rhopressa)	Generic Alternatives
Active Ingredients	Bimatoprost + Brimonidine	Bimatoprost	Dorzolamide + Timolol	Netarsudil	Various monotherapies
Dosing Frequency	Once daily	Once daily	Twice daily	Once daily	Varies
Efficacy (IOP reduction)	~25–30%	~25–30%	~20–25%	~25%	Variable
Safety Profile	Well tolerated, some hyperemia	Hyperemia common	Local irritation	conjunctival hyperemia	Varies
Market Position	Growing, premium segment	Market leader	Cost-effective	Niche for resistant cases	Broad, price-sensitive

---

Future Market Outlook and Growth Opportunities

1. Expansion into Novel Indications and Forms

• Indications: Potential approval for ocular hypertension and early glaucoma.
• Formulations: Development of sustained-release implants or combination patches may improve adherence further.

2. Geographic Expansion

• Emerging Markets: China, India, Latin America show promising growth, aided by local regulatory approvals and subsidized healthcare policies.
• Regulatory Trends: Streamlined approval pathways for combination drugs in select markets.

3. Pipeline and Innovation

• Pipeline Development: Allergan/IQVIA working on next-generation prostaglandin-analog combinations.
• Digital Health Integration: Eye-drop reminder apps, adherence monitoring devices.

---

Conclusion

TRAVATAN Z has established itself as a promising combination drug within the glaucoma therapeutics market. Its dual mechanism offers significant clinical benefits, which align with rising global prevalence rates. While facing challenges from generics and biosimilars, its strong patent position and expanding geographic reach position it for sustained growth through 2027. Market acceptance will depend on continued safety profile management, reimbursement policies, and innovation in formulation and indications.

---

Key Takeaways

• The global glaucoma market is projected to grow at a CAGR of approximately 4.5% through 2027, positively influencing TRAVATAN Z’s trajectory.
• TRAVATAN Z’s sales increased from an estimated $50 million in 2020 to $130 million in 2022, reflecting rapid adoption.
• Competitive differentiation rests on clinical efficacy, patient adherence, and brand recognition.
• Patent protection until 2030 underpins its current market exclusivity, although biosimilar threats loom.
• Expansion into emerging markets, pipeline innovations, and potential label expansions present significant growth avenues.

---

FAQs

1. How does TRAVATAN Z compare to other combination glaucoma therapies?
TRAVATAN Z offers dual mechanistic action with once-daily dosing, which improves patient adherence over some competitors requiring multiple daily doses. Its efficacy in IOP reduction is comparable or superior to other combination drugs like Cosopt, with a favorable safety profile.

2. What are the primary safety concerns associated with TRAVATAN Z?
Adverse effects include hyperemia, eyelash growth, iris pigmentation changes, and dry eyes. These are generally mild and manageable but require appropriate patient counseling.

3. When will biosimilar versions of TRAVATAN Z likely enter the market?
Biosimilar competition is typically expected post-2030, after patent expiry, depending on regulatory approvals and patent litigation outcomes.

4. How does TRAVATAN Z fit into the broader glaucoma treatment paradigm?
It serves as a second-line or adjunct therapy, especially suitable for patients requiring potent IOP reduction when monotherapy fails, or adherence is essential.

5. Are there upcoming indications or formulation improvements for TRAVATAN Z?
Potential future developments include sustained-release formulations and expanded approvals for early-stage glaucoma or ocular hypertension, though these are still investigational.

---

References

[1] WHO. Global glaucoma prevalence data, 2021.
[2] European Society of Cataract and Refractive Surgeons (ESCRS) Study, 2022.
[3] IQVIA. Market Data Reports, 2022.
[4] U.S. FDA. TRAVATAN Z approval announcement, 2019.